HC Wainwright set a $37.00 price target on Audentes Therapeutics (NASDAQ:BOLD) in a research note issued to investors on Thursday. The firm currently has a buy rating on the biotechnology company’s stock.
Several other research analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Audentes Therapeutics from a hold rating to a sell rating in a research report on Friday, November 17th. BidaskClub lowered shares of Audentes Therapeutics from a strong-buy rating to a buy rating in a research report on Wednesday, December 6th. Bank of America restated a buy rating and set a $33.00 target price (up from $23.00) on shares of Audentes Therapeutics in a research report on Friday, September 22nd. Leerink Swann restated an outperform rating and set a $29.00 target price (up from $22.00) on shares of Audentes Therapeutics in a research report on Wednesday, November 15th. Finally, Raymond James Financial initiated coverage on shares of Audentes Therapeutics in a research report on Thursday, October 12th. They issued a market perform rating on the stock. Two research analysts have rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $35.00.
Audentes Therapeutics (NASDAQ BOLD) opened at $36.63 on Thursday. Audentes Therapeutics has a 1 year low of $13.90 and a 1 year high of $41.80. The firm has a market cap of $1,093.45, a PE ratio of -10.50 and a beta of -0.21.
Audentes Therapeutics (NASDAQ:BOLD) last issued its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share for the quarter, hitting the consensus estimate of ($0.88). research analysts forecast that Audentes Therapeutics will post -3.5 EPS for the current fiscal year.
In other news, VP Suyash Prasad sold 8,000 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $28.53, for a total value of $228,240.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Mary Newman sold 10,000 shares of the stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $26.84, for a total transaction of $268,400.00. The disclosure for this sale can be found here. Insiders sold 36,000 shares of company stock worth $1,052,480 over the last quarter. Company insiders own 47.30% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in BOLD. SG Americas Securities LLC purchased a new position in shares of Audentes Therapeutics during the third quarter valued at approximately $143,000. Nationwide Fund Advisors lifted its stake in shares of Audentes Therapeutics by 288.9% during the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after buying an additional 6,384 shares during the period. State of Wisconsin Investment Board purchased a new position in shares of Audentes Therapeutics during the second quarter valued at approximately $210,000. Rhumbline Advisers purchased a new position in shares of Audentes Therapeutics during the second quarter valued at approximately $252,000. Finally, Virtu KCG Holdings LLC purchased a new position in shares of Audentes Therapeutics during the second quarter valued at approximately $257,000. 78.95% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “Audentes Therapeutics (BOLD) PT Set at $37.00 by HC Wainwright” was first posted by Equities Focus and is owned by of Equities Focus. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.equitiesfocus.com/2018/01/08/audentes-therapeutics-bold-pt-set-at-37-00-by-hc-wainwright.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.